<DOC>
	<DOCNO>NCT02381418</DOCNO>
	<brief_summary>Influenza ( flu ) viruses change continuously , therefore also part virus use influenza vaccine vary year year . The current study phase III A clinical trial commercially available vaccine ( Influvac® ) supply pre fill syrinx . The objective study investigate immunogenicity safety tolerability change influenza vaccine virus composition two group subject good health : subject age &gt; = 18 &lt; = 60 year subject &gt; = 61 year age ( elderly ) .</brief_summary>
	<brief_title>Annual Study Investigate Inactivated Subunit Influenza Vaccine Due New Virus Strains Southern Hemisphere 2015 Season</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing able give inform consent able adhere protocol require study procedure . Men woman age ≥ 18 ≤ 60 year ≥ 61 year age day study vaccination . Being good health judge medical history , physical examination ( need ) clinical judgment Investigator Known allergic egg , chicken protein , gentamicin constituent vaccine . A serious adverse reaction previous ( influenza ) vaccination . Presence significant condition may prohibit inclusion determine investigator . Seasonal pandemic influenza vaccination laboratory confirm seasonal pandemic influenza infection within previous six month study vaccination plan vaccination study period . A history GuillainBarré syndrome active neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Committee Medicinal Products Human Use ( CHMP ) criterion</keyword>
</DOC>